PharmaCyte Biotech (PMCB) Times Interest Earned (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Times Interest Earned of -$0.13 for Q2 2026, down 89.44% year-over-year from -$1.23 in Q2 2025, and down 89.44% quarter-over-quarter from -$0.07 in Q2 2025.
PharmaCyte Biotech (PMCB) Times Interest Earned (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Times Interest Earned for 16 consecutive years, with -$0.13 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned fell 89.44% year-over-year to -$0.13; the TTM figure through Apr 2026 stood at -$0.35 (down 23.06% YoY), while the FY2026 annual figure was -$0.35, down 23.04% from the prior year.
- Times Interest Earned retreated to -$0.13 in Q2 2026 per PMCB's latest filing, from -$0.07 in the prior quarter.
- Across five years, Times Interest Earned topped out at $312.85 in Q1 2023 and bottomed at -$1001.1 in Q4 2022.
- Historically, Times Interest Earned has averaged -$188.61 across 5 years, with a median of -$0.21 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned sank 585.46% — and 2023, when it surged 255.42%.
- PharmaCyte Biotech's Times Interest Earned stood at -$1001.1 in 2022, then surged by 131.25% to $312.85 in 2023, then tumbled by 100.07% to -$0.21 in 2024, then jumped by 67.15% to -$0.07 in 2025, then sank by 89.44% to -$0.13 in 2026.
- Business Quant data shows PMCB's Times Interest Earned at -$0.13 in Q2 2026, -$0.07 in Q2 2025, and -$0.21 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -0.13 |
| Apr 30, 2025 | -0.07 |
| Apr 30, 2024 | -0.21 |
| Jan 31, 2023 | 312.85 |
| Oct 31, 2022 | -1,001.13 |
| Jul 31, 2022 | -430.26 |
| Jan 31, 2022 | -201.30 |
| Oct 31, 2021 | -146.05 |
| Jul 31, 2021 | -639.59 |
| Apr 30, 2021 | -3,965.30 |
| Jan 31, 2021 | -201.08 |
| Oct 31, 2020 | -184.59 |
| Jul 31, 2020 | -70.78 |
| Apr 30, 2020 | -1,655.39 |
| Apr 30, 2019 | -0.08 |
| Jan 31, 2019 | -35.05 |
| Apr 30, 2017 | -2,390.35 |
| Jan 31, 2017 | -9,786.37 |
| Oct 31, 2016 | -2,736.50 |
| Jul 31, 2016 | -1,812.65 |